BioXcel names Mark Pavao Interim CCO; plans sNDA for IGALMI at-home use

BioXcel Therapeutics, Inc.

Mark Pavao appointed Interim Chief Commercial Officer to support potential IGALMI at-home launch.
Company plans to submit supplemental NDA this month for FDA approval of IGALMI for at-home use.
IGALMI targets acute agitation in bipolar disorders or schizophrenia; at-home expansion is key strategic move.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.